*Dr. Jyoti Sharma, Dr. Pulkit Kaushal and Dr. Jyoti Kaushal


Parkinson‘s disease is the second most common neurodegenerative disease. There is a loss of nigrostriatal neurons leading to motor deficits such as rigidity, tremors, bradykinesia. The exact cause of parkinson‘s disease (PD) is unknown in most of the cases. The most commonly used treatment of Parkinson disease is dopamine replacement therapy. The commonly used drugs are levodopa, COMT inhibitors, MAO inhibitors etc. Drugs like levodopa which is the mainstay of PD therapy, loses efficacy over a period of time and causes dyskinesias and behavioural problems & ultimately development of both motor and non-motor problems. Moreover, available therapies do not prevent neuron degeneration and provide only symptomatic relief. The new PD treatment should tackle the two unresolved problems, one is moving from symptom alleviating to disease modification and the second is to reduce the growing prevalence of non-motor disease symptoms such as loss of balance, autonomic dysfunction and cognitive impairment. The newer emerging therapies for the treatment of Parkinson‘s disease are Neuroprotective agents like Coenzyme Q10, Adenosine receptor antagonists, Neurotrophic factors, Glutamate antagonists, Antioxidants, PDE inhibitors, Monoclonal antibodies, Safinamide and Gene therapy. Several obstacles in developing therapies for Parkinson‘s exist, which include: a lack of a clear understanding about the biological processes leading to neuronal loss and a lack of a biomarker for determining progression and severity of the disease. Hence, despite availability of numerous effective drugs which provide short term relief; still research is going on to develop promising drugs and newer strategies to provide long term benefit by modifying the disease process.

Keywords: Parkinson‘s disease, Neurotrophic, Neuroprotective.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    MAY 2022 Issue has been successfully launched on 1 May 2022.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction